MX2015000969A - Quinone compounds and their uses for the treatment of cancer. - Google Patents
Quinone compounds and their uses for the treatment of cancer.Info
- Publication number
- MX2015000969A MX2015000969A MX2015000969A MX2015000969A MX2015000969A MX 2015000969 A MX2015000969 A MX 2015000969A MX 2015000969 A MX2015000969 A MX 2015000969A MX 2015000969 A MX2015000969 A MX 2015000969A MX 2015000969 A MX2015000969 A MX 2015000969A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- quinone compounds
- compounds
- quinone
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000004053 quinones Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Quinone Compounds and Their Uses for the Treatment of Cancer Quinone compounds having useful therapeutic activity such as anticancer activity, and compositions comprising such compounds, are described. The use of such compounds and compositions in the treatment of cancer is also described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1213486.2A GB201213486D0 (en) | 2012-07-30 | 2012-07-30 | Quinone compounds and their uses for the treatment of cancer |
| PCT/EP2013/065968 WO2014020012A1 (en) | 2012-07-30 | 2013-07-30 | Quinone compounds and their uses for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000969A true MX2015000969A (en) | 2015-09-23 |
| MX361650B MX361650B (en) | 2018-12-13 |
Family
ID=46881339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000969A MX361650B (en) | 2012-07-30 | 2013-07-30 | Quinone compounds and their uses for the treatment of cancer. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9266829B2 (en) |
| EP (1) | EP2882743B1 (en) |
| JP (1) | JP6317742B2 (en) |
| KR (1) | KR102142164B1 (en) |
| CN (1) | CN104583200B (en) |
| AU (1) | AU2013298653B2 (en) |
| BR (1) | BR112015001837B1 (en) |
| CA (1) | CA2880021C (en) |
| DK (1) | DK2882743T3 (en) |
| ES (1) | ES2662917T3 (en) |
| GB (2) | GB201213486D0 (en) |
| IN (1) | IN2015DN01223A (en) |
| MX (1) | MX361650B (en) |
| NO (1) | NO2882743T3 (en) |
| RU (1) | RU2688675C2 (en) |
| WO (1) | WO2014020012A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887684B (en) * | 2022-12-02 | 2025-02-14 | 南京邮电大学 | Drug delivery nanosystem and method based on DNA origami and doxorubicin prodrug |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156744A (en) * | 1998-03-19 | 2000-12-05 | Cancer Research Campaign Tech (London) | DT-diaphorase directed anti-tumor agents |
| AU2005265155A1 (en) * | 2004-06-21 | 2006-01-26 | Hutchison Medipharma Enterprises Limited | Cancer chemotherapy |
| EP2134322B1 (en) * | 2007-03-13 | 2019-02-20 | Spectrum Pharmaceuticals, Inc. | Intravesical apaziquone administration following transurethral resection for treating bladder cancer |
-
2012
- 2012-07-30 GB GBGB1213486.2A patent/GB201213486D0/en not_active Ceased
-
2013
- 2013-07-30 MX MX2015000969A patent/MX361650B/en active IP Right Grant
- 2013-07-30 JP JP2015524762A patent/JP6317742B2/en not_active Expired - Fee Related
- 2013-07-30 ES ES13742640.9T patent/ES2662917T3/en active Active
- 2013-07-30 US US14/418,394 patent/US9266829B2/en not_active Expired - Fee Related
- 2013-07-30 NO NO13742640A patent/NO2882743T3/no unknown
- 2013-07-30 IN IN1223DEN2015 patent/IN2015DN01223A/en unknown
- 2013-07-30 AU AU2013298653A patent/AU2013298653B2/en not_active Ceased
- 2013-07-30 RU RU2015105036A patent/RU2688675C2/en not_active IP Right Cessation
- 2013-07-30 EP EP13742640.9A patent/EP2882743B1/en not_active Not-in-force
- 2013-07-30 BR BR112015001837-8A patent/BR112015001837B1/en not_active IP Right Cessation
- 2013-07-30 CN CN201380040388.1A patent/CN104583200B/en not_active Expired - Fee Related
- 2013-07-30 DK DK13742640.9T patent/DK2882743T3/en active
- 2013-07-30 GB GB1422799.5A patent/GB2519004B/en not_active Expired - Fee Related
- 2013-07-30 WO PCT/EP2013/065968 patent/WO2014020012A1/en not_active Ceased
- 2013-07-30 KR KR1020157002128A patent/KR102142164B1/en not_active Expired - Fee Related
- 2013-07-30 CA CA2880021A patent/CA2880021C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB2519004B (en) | 2016-03-30 |
| CA2880021A1 (en) | 2014-02-06 |
| ES2662917T3 (en) | 2018-04-10 |
| NO2882743T3 (en) | 2018-05-12 |
| BR112015001837A2 (en) | 2017-07-04 |
| BR112015001837B1 (en) | 2021-11-16 |
| GB2519004A (en) | 2015-04-08 |
| EP2882743B1 (en) | 2017-12-13 |
| EP2882743A1 (en) | 2015-06-17 |
| IN2015DN01223A (en) | 2015-06-26 |
| DK2882743T3 (en) | 2018-03-12 |
| KR102142164B1 (en) | 2020-08-06 |
| JP2015524815A (en) | 2015-08-27 |
| RU2015105036A (en) | 2016-09-20 |
| AU2013298653A1 (en) | 2015-02-19 |
| CN104583200A (en) | 2015-04-29 |
| WO2014020012A1 (en) | 2014-02-06 |
| CA2880021C (en) | 2020-01-14 |
| RU2688675C2 (en) | 2019-05-22 |
| JP6317742B2 (en) | 2018-04-25 |
| MX361650B (en) | 2018-12-13 |
| GB201213486D0 (en) | 2012-09-12 |
| US9266829B2 (en) | 2016-02-23 |
| US20150210639A1 (en) | 2015-07-30 |
| CN104583200B (en) | 2017-07-25 |
| HK1209111A1 (en) | 2016-03-24 |
| AU2013298653B2 (en) | 2017-10-19 |
| KR20150036215A (en) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2021002713A (en) | Androgen receptor modulator and uses thereof. | |
| GB201209613D0 (en) | New compounds | |
| MX2020010535A (en) | Methods of treating cancer. | |
| MY188363A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX366804B (en) | R-spondin translocations and methods using the same. | |
| MX366899B (en) | New compounds. | |
| MY176489A (en) | Novel tricyclic compounds as anticancer agents | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| MX2014012477A (en) | Pyrrolopyrazone inhibitors of tankyrase. | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| IN2014DN06104A (en) | ||
| MX2014008705A (en) | Tricyclic sulfone compounds and methods of making and using same. | |
| MX356755B (en) | Fumigillol type compounds and methods of making and using same. | |
| MX365392B (en) | Procaspase 3 activation by combination therapy. | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| IN2014MN01944A (en) | ||
| MX2015005732A (en) | Tricyclic compounds and methods of making and using same. | |
| MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
| MX2013003859A (en) | Picropodophyllin polymorphs b or c for use in cancer therapy. | |
| GB2519004A (en) | Quinone compounds and their uses for the treatment of cancer | |
| HK1209111B (en) | Quinone compounds and their uses for the treatment of cancer | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |